12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States.

      Journal of Occupational and Environmental Medicine
      Analgesics, Opioid, economics, Anti-Inflammatory Agents, Non-Steroidal, Cost of Illness, Costs and Cost Analysis, Cyclooxygenase 2, Female, Humans, Insurance Claim Review, Insurance Coverage, Male, Middle Aged, Osteoarthritis, drug therapy, physiopathology, Pain, Tramadol, United States

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To assess the health care utilization and cost of illness for osteoarthritis (OA) patients taking pain medications. Specifically, the goals were to estimate the direct health care and indirect costs of OA. A claims database of privately insured patients was used to identify OA patients. Prescription drug pain treatments included tramadol, cyclooxygenase-II inhibitors, and nonsteroidal anti-inflammatory drugs. Mean annual per patient costs were calculated from an employer's perspective. OA patients were prescribed multiple drugs simultaneously and/or sequentially to manage pain. OA patients had a number of prevalent comorbid conditions. Average annual direct medical, drug, and indirect work loss costs were $8601, $2941, and $4603, respectively. There was a substantial payer burden associated with OA resulting from the drug, medical, and disability costs and OA-related comorbidities and high concomitant medication utilization.

          Related collections

          Author and article information

          Comments

          Comment on this article